Aspira Women's Health Files Q1 2025 10-Q

Ticker: AWHL · Form: 10-Q · Filed: 2025-05-19T00:00:00.000Z

Sentiment: neutral

Topics: 10-Q, financials, diagnostics

TL;DR

Aspira Women's Health filed its Q1 2025 10-Q. Financials and operations update.

AI Summary

Aspira Women's Health Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Vermillion, Inc., is involved in in vitro & in vivo diagnostic substances. Its principal executive offices are located in Austin, Texas.

Why It Matters

This filing provides an update on Aspira Women's Health's financial performance and operational status for the first quarter of 2025, crucial for investors tracking the company's progress in the diagnostics sector.

Risk Assessment

Risk Level: low — This is a standard quarterly financial filing with no immediate red flags or significant new information presented.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Aspira Women's Health Inc.?

Aspira Women's Health Inc. is involved in in vitro & in vivo diagnostic substances, as indicated by its Standard Industrial Classification code.

When was the current 10-Q filing submitted to the SEC?

The 10-Q filing was submitted on May 19, 2025.

What is the fiscal year end for Aspira Women's Health Inc.?

The company's fiscal year ends on December 31.

What were the previous names of Aspira Women's Health Inc.?

Aspira Women's Health Inc. was formerly known as VERMILLION, INC., CIPHERGEN BIOSYSTEMS INC, and ABIOTIC SYSTEMS.

Where are Aspira Women's Health Inc.'s principal executive offices located?

The company's principal executive offices are located at 12117 Bee Caves Road, Building Three, Suite 100, Austin, TX 78738.

From the Filing

0001641172-25-011399.txt : 20250519 0001641172-25-011399.hdr.sgml : 20250519 20250519092256 ACCESSION NUMBER: 0001641172-25-011399 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250519 DATE AS OF CHANGE: 20250519 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences EIN: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34810 FILM NUMBER: 25961831 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 10-Q 1 form10-q.htm 10-Q false --12-31 Q1 0000926617 0000926617 2025-01-01 2025-03-31 0000926617 2025-05-12 0000926617 2025-03-31 0000926617 2024-12-31 0000926617 2024-01-01 2024-03-31 0000926617 us-gaap:ProductMember 2025-01-01 2025-03-31 0000926617 us-gaap:ProductMember 2024-01-01 2024-03-31 0000926617 us-gaap:CommonStockMember 2024-12-31 0000926617 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000926617 us-gaap:RetainedEarningsMember 2024-12-31 0000926617 us-gaap:CommonStockMember 2023-12-31 0000926617 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000926617 us-gaap:RetainedEarningsMember 2023-12-31 0000926617 2023-12-31 0000926617 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000926617 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000926617 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000926617 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000926617 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000926617 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000926617 us-gaap:CommonStockMember 2025-03-31 0000926617 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000926617 us-gaap:RetainedEarningsMember 2025-03-31 0000926617 us-gaap:CommonStockMember 2024-03-31 0000926617 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000926617 us-gaap:RetainedEarningsMember 2024-03-31 0000926617 2024-03-31 0000926617 AWHL:EquityLineOfCreditAgreementMember 2025-01-01 2025-03-31 0000926617 AWHL:EquityLineOfCreditAgreementMember 2024-01-01 2024-03-31 0000926617 AWHL:TwoThousandTwentyFourDirectOfferingMember 2025-01-01 2025-03-31 0000926617 AWHL:TwoThousandTwentyFourDirectOfferingMember 2024-01-01 2024-03-31 0000926617 AWHL:TwoThousandTwentyFourAtTheMarketOfferingAgreementMember 2025-01-01 2025-03-31 0000926617 AWHL:TwoThousandTwentyFourAtTheMarketOfferingAgreementMember 2024-01-01 2024-03-31 0000926617 us-gaap:AccountingStandardsUpdate202203Member 2025-03-31 0000926617 us-gaap:AccountingStandardsUpdate202301Member 2025-03-31 0000926617 AWHL:ModifiedWarrantsMember 2024-12-31 0000926617 AWHL:UnmodifiedWarrantsMember 2024-12-31 0000926617 AWHL:ModifiedWarrantsMember 2024-08-31 0000926617 AWHL:TwoThousandAndTwentyTwoWarrantsMember 2025-03-31 0000926617 AWHL:TwoThousandAndTwentyTwoWarrantsMember 2024-12-31 0000926617 srt:MaximumMember AWHL:MarchTwoThousandAndTwentyFiveWarrantsMember 2025-03-31 0000926617 AWHL:MarchTwoThousandAndTwentyFiveWarrantsMember 2025-03-31 0000926617 AWHL:MarchTwoThousandAndTwentyFiveWarrantsMember us-gaap:WarrantMember 2025-03-31 0000926617 AWHL:MarchTwoThousandAndTwentyFiveWarrantsMember 2025-03-31 0000926617 AWHL:MarchTwoThousandAndTwentyFiveWarrantsMember 2025-03-12 0000926617 us-gaap:ConvertibleDebtMember 2025-01-01 2025-03-31 0000926617 AWHL:TwoThousandTwentyTwoWarrantsMember 2025-01-01 2025-03-

View on Read The Filing